Loading
Leads the German CLL Study Group, whose trials (CLL8, CLL14, CLL13) set global standards for CLL treatment.
Michael Hallek is Director of Department I of Internal Medicine at University Hospital Cologne (CIO) and Head of the German CLL Study Group. His specialisms are chronic lymphocytic leukaemia, chemoimmunotherapy and targeted therapy trials, with a focus on BCL-2 and CD20. He led CLL8, which established the FCR regimen, CLL14, the New England Journal of Medicine trial of venetoclax and obinutuzumab in patients with CLL and coexisting conditions, and CLL13/GAIA. These trials moved CLL from chemotherapy to fixed-duration targeted therapy and set global standards. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Venetoclax and obinutuzumab in patients with CLL and coexisting conditions (CLL14) | NEJM | 2019 |
Shares CLL14, CLL13 / GAIA, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, Obinutuzumab.
Shares Uniklinik Köln (CIO), CLL14, CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, BCL-2.
Shares Uniklinik Köln (CIO), CLL13 / GAIA, BCL-2, CD20.
Shares CLL14, CLL13 / GAIA, Chronic lymphocytic leukaemia.
Shares CLL13 / GAIA, Obinutuzumab, BCL-2, CD20.
Shares Obinutuzumab, BCL-2, CD20, Venetoclax.
Shares BCL-2, CD20, Venetoclax, Chronic lymphocytic leukaemia.
Shares CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients, BCL-2, CD20, Venetoclax.